Associated Papers
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
41326340 (PubMed )
Supplement: 41392_2025_2481_MOESM1_ESM.docx
Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
Williams EA et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2020
32483240 (PubMed )
Supplement: 41379_2020_581_MOESM5_ESM.xlsx › Sheet1
Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma.
Jian H et al.
Anti-cancer Drugs, 2019
Select a paper to view details